Form 4: Oragenics Director Alan Dunton Acquires Options in Latest Transaction
SEC Form 4
Director Alan Dunton reports acquisition of options to purchase 65,000 shares of Oragenics Inc. common stock.
Summary
- On September 19, 2024, Alan Dunton, a director of Oragenics Inc. (OGEN), acquired options to purchase 65,000 shares of the company's common stock.
- The options were granted under the company's 2021 Equity Incentive Plan, as amended, as part of the non-employee director compensation program.
- The exercise price of the options is $0.48, which is the closing price of Oragenics' stock on the grant date.
- The options vest immediately and expire on September 19, 2034.
Sentiment
Score: 6
Explanation: The sentiment is neutral. It's a standard transaction related to director compensation. There's no indication of positive or negative implications for the company's performance.
Positives
- The immediate vesting of the options could incentivize the director to work towards the company's success.
- The grant aligns the director's interests with those of the shareholders.
Industry Context
This transaction is a routine part of director compensation, aligning their interests with shareholders through equity ownership. It's common for companies to use stock options as part of their compensation packages for directors and executives.
Comparison to Industry Standards
- Granting options to non-employee directors is a common practice to align their interests with shareholders, similar to companies like Amgen and Biogen who also use equity-based compensation.
- The vesting schedule of immediately vested options is comparable to some companies, while others may have a phased vesting over several years, similar to the vesting schedules at Regeneron Pharmaceuticals.
Stakeholder Impact
- The option grant aligns the director's interests with those of shareholders, potentially encouraging decisions that increase shareholder value.
Key Dates
| Date | Description |
|---|---|
| 09/19/2024 | Date of the transaction: Alan Dunton acquired options to purchase Oragenics Inc. common stock. |
| 09/19/2024 | Options vest immediately. |
| 09/19/2034 | Expiration date of the options. |
| 09/20/2024 | Date of signature on the Form 4 filing. |
Keywords
Oragenics, OGEN, Alan Dunton, Director, Options, Equity Incentive Plan, Beneficial Ownership, Form 4
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.